Background: Studies of acute venous thromboembolism (VTE) and non-valvular atrial
fibrillation (AF) have shown comparable therapeutic efficacy and similar or lower bleeding …

Background Atrial fibrillation and heart failure are combined risk factors for thromboembolic
events. Obese and morbidly obese individuals have been underrepresented in clinical trials …

Introduction Recommendations about proper anticoagulation in obese patients, body mass
index (BMI)> 30 kg/m2, are not yet clearly defined. Obese patients were included in …

Atrial fibrillation (AF) is a cardiac condition characterized by an irregular heart rhythm, which
is increasingly prevalent in the modern era. All international guidelines strongly advise the …

Highlights•Direct oral anticoagulants did not increase stroke or systemic embolism event
rate.•Direct oral anticoagulants had lower major bleeding rate than warfarin.•Direct oral …

Background: Obesity is an independent risk factor for atrial fibrillation (AF) influencing the
pharmacokinetics and pharmacodynamics of drug therapy and direct oral anticoagulants …

Background and Purpose—Obesity is a risk factor for all-cause and cardiovascular death
but, despite this, an inverse relationship between overweight or obesity and a better …

In this issue of the journal, we focus on different aspects of atrial fibrillation (AF). 1–3 Data
from epidemiological cohorts support the role of obesity as an independent risk factor for AF …

Background: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …

■ After applying selection criteria, a total of 62,143 obese patients (19.3%) with NVAF were
included: 13,130 (21.1%) apixaban, 5,349 (8.6%) dabigatran, 20,278 (32.6%) rivaroxaban …